LivaNova LIVN Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net revenue by Business | ||||||
| Cardiopulmonary | $208.66M+1.0% | $206.58M+1.7% | $203.22M+2.0% | $199.27M+13.0% | $176.32M-2.9% | |
| Neuromodulation | $151.79M-0.6% | $152.72M+2.1% | $149.53M-1.4% | $151.67M+9.2% | $138.89M+0.9% | |
| Operating Income by Business | ||||||
| Cardiopulmonary | $30.07M+9.3% | $27.51M+11.4% | $24.7M-21.4% | $31.41M+27.2% | $24.69M+18.5% | |
| Neuromodulation | $44.15M-13.3% | $50.92M-9.4% | $56.19M+0.3% | $56.02M+7.0% | $52.35M+18.2% | |
| Total Assets by Business | ||||||
| Cardiopulmonary | $1.05B+0.1% | $1.05B+2.6% | $1.02B+0.5% | $1.01B+7.9% | $939.84M+4.3% | |
| Neuromodulation | $650.1M+1.6% | $639.74M0.0% | $639.97M+0.4% | $637.72M-0.6% | $641.88M+0.1% | |
| Selling, general, and administrative by Business | ||||||
| Cardiopulmonary | $59.85M+5.5% | $56.71M-3.2% | $58.58M+4.6% | $56.01M-4.2% | $58.48M-16.8% | |
| Neuromodulation | $52.62M-2.5% | $53.99M+8.1% | $49.94M-2.3% | $51.1M+7.4% | $47.57M-5.5% | |
| Cost of Sales by Business | ||||||
| Cardiopulmonary | $100.93M-2.2% | $103.24M+5.2% | $98.09M+2.7% | $95.47M+12.4% | $84.92M-6.1% | |
| Neuromodulation | $14.22M-5.0% | $14.97M+17.9% | $12.69M-14.1% | $14.77M+10.3% | $13.39M-18.0% | |
| R&D by Business | ||||||
| Cardiopulmonary | $17.8M-6.9% | $19.12M+5.6% | $18.11M+10.0% | $16.47M+36.7% | $12.04M-17.3% | |
| Neuromodulation | $40.79M+24.2% | $32.85M+7.0% | $30.71M+3.1% | $29.78M+16.4% | $25.58M-4.1% | |
| Foreign currency adjustments by Business | ||||||
| Cardiopulmonary | -$7.25M— | —— | —— | $31.45M+164% | $11.91M— | |
| Neuromodulation | $0— | —— | $0— | $0— | $0— | |
| 3T litigation provision by Business | ||||||
| Cardiopulmonary | $15K+200% | $5K-99.9% | $3.74M+4,962% | -$77K-111% | $706K-75.6% | |
| Neuromodulation | $0— | $0— | $0— | $0— | $0— | |
| CapEx by Business | ||||||
| Cardiopulmonary | $10.41M-50.6% | $21.08M+122% | $9.5M+8.3% | $8.77M+69.6% | $5.17M-45.2% | |
| Neuromodulation | $8.84M+82.5% | $4.85M+2.3% | $4.74M+12.4% | $4.22M+107% | $2.03M+9.1% | |
| Goodwill by Business | ||||||
| Cardiopulmonary | $386.84M-1.8% | $394.09M+0.5% | $392.28M-0.6% | $394.61M+8.7% | $363.16M+3.4% | |
| Neuromodulation | $398.75M0.0% | $398.75M0.0% | $398.75M0.0% | $398.75M0.0% | $398.75M0.0% | |
| Net revenue by Geography | ||||||
| Europe | $75.65M+0.8% | $75.02M+10.8% | $67.68M+1.4% | $66.78M+11.9% | $59.7M-3.1% | |
| Rest of World | $101.93M+8.0% | $94.42M-5.2% | $99.62M+2.4% | $97.27M+10.6% | $87.99M+3.4% | |
| United States | $184.68M-3.6% | $191.49M+0.5% | $190.45M+1.0% | $188.47M+11.4% | $169.16M-3.4% | |
| Property, Plant and Equipment, Net by Geography | ||||||
| Europe | $152.89M+3.8% | $147.3M+13.9% | $129.27M+16.8% | $110.67M+9.9% | $100.7M+6.7% | |
| Rest of World | $16.19M+2.5% | $15.8M+5.8% | $14.94M+2.9% | $14.52M+29.7% | $11.2M+4.7% | |
| United States | $86.4M+8.7% | $79.5M+7.0% | $74.3M+5.8% | $70.23M+6.7% | $65.79M+1.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does LivaNova break its business down?
- LivaNova (LIVN) reports net revenue by business across 2 parts — Cardiopulmonary and Neuromodulation. Each is extracted from the segment footnotes and tracked over time.
- Where does LivaNova's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in LivaNova's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.